Evidence map›Paper›PMID 36529846›Full record

SynthesisPurinergic signalling2023

Transactivation of receptor tyrosine kinases by purinergic P2Y and adenosine receptors.

F G Vázquez-Cuevas, M Reyna-Jeldes, E Velázquez-Miranda, C Coddou

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in Purinergic signalling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

F G Vázquez-CuevasDepartamento de Neurobiología Celular Y Molecular, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla # 3001, Juriquilla, Querétaro, 76230, México. fvazquez@comunidad.unam.mx.
M Reyna-JeldesDepartamento de Ciencias Biomédicas, Facultad de Medicina, Universidad Católica del Norte, Larrondo 1281, Coquimbo, 1781421, Chile.
E Velázquez-MirandaDepartamento de Neurobiología Celular Y Molecular, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla # 3001, Juriquilla, Querétaro, 76230, México.
C CoddouDepartamento de Ciencias Biomédicas, Facultad de Medicina, Universidad Católica del Norte, Larrondo 1281, Coquimbo, 1781421, Chile. ccoddou@ucn.cl.
Universidad Católica del Norte · CLUniversidad Nacional Autónoma de México · MX

Funding

Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México IN202620 and IN205223Millennium Nucleus for the Study of Pain (MiNuSPain). NCN19_038Núcleo para el Estudio del Cáncer a Nivel Básico, Aplicado y Clínico VRIDT UCN 20210401007
6 · The paper itself

Abstract

Transactivation of receptor tyrosine kinases (RTK) is a crosstalk mechanism exhibited by G-protein-coupled receptors (GPCR) to activate signaling pathways classically associated with growth factors. The discovery of RTK transactivation was a breakthrough in signal transduction that contributed to developing current concepts in intracellular signaling. RTK transactivation links GPCR signaling to important cellular processes, such as cell proliferation and differentiation, and explains the functional diversity of these receptors. Purinergic (P2Y and adenosine) receptors belong to class A of GPCR; in the present work, we systematically review the experimental evidence showing that purinergic receptors have the ability to transactivate RTK in multiple tissues and physiopathological conditions resulting in the modulation of cellular physiology. Of particular relevance, the crosstalk between purinergic receptors and epidermal growth factor receptor is a redundant pathway that participates in multiple pathophysiological processes. Specific and detailed knowledge of purinergic receptor-regulated pathways advances our understanding of the complexity of GPCR signal transduction and opens the way for pharmacologic intervention in the pathological context.

Indexed as

Receptor Protein-Tyrosine KinasesSignal TransductionReceptors, G-Protein-CoupledReceptors, Purinergic P1Transcriptional ActivationTyrosineReceptor Protein-Tyrosine KinasesReceptors, G-Protein-CoupledReceptors, Purinergic P1TyrosineAdenosine receptorsEGFRGPCRP2Y receptorPurinergic receptorsRTKTransactivation

Identifiers

PMID36529846
PMCPMC10754767
OpenAlexW4311927369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.